专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US09181229B2 Azole derivative 有权
标题翻译：唑类衍生物
公开(公告)号：US09181229B2
公开(公告)日：2015-11-10
申请号：US14004997
申请日：2012-03-15
申请人： Naoya Ono , Shoichi Kuroda , Yoshihisa Shirasaki , Tetsuo Takayama , Yoshinori Sekiguchi , Fumihito Ushiyama , Yusuke Oka
发明人： Naoya Ono , Shoichi Kuroda , Yoshihisa Shirasaki , Tetsuo Takayama , Yoshinori Sekiguchi , Fumihito Ushiyama , Yusuke Oka
IPC分类号： C07D413/04 , C07D403/04 , C07D417/04 , C07D413/14
CPC分类号： C07D413/04 , C07D403/04 , C07D413/14 , C07D417/04
摘要： Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where R1 represents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.
摘要翻译：提供与FKBP12或其药学上可接受的盐结合的新化合物，以及可用于预防或治疗脱发的新治疗剂，其包含那些化合物或其药学上可接受的盐。具体地，提供由式（1）表示的化合物[其中R 1表示下式（2）或（3）]或其药学上可接受的盐。

32. 发明授权

US09045466B2 Amidine compound or salt thereof 有权
标题翻译：脒化合物或其盐
公开(公告)号：US09045466B2
公开(公告)日：2015-06-02
申请号：US14235686
申请日：2012-07-27
申请人： Tetsuya Tanikawa , Yasunobu Ushiki , Fumihito Ushiyama , Toru Yamaguchi , Naoya Ono , Keiko Yamamoto , Risa Tsuruta , Yasuhiro Tsutsui , Noritomo Fujino , Ayumu Mori
发明人： Tetsuya Tanikawa , Yasunobu Ushiki , Fumihito Ushiyama , Toru Yamaguchi , Naoya Ono , Keiko Yamamoto , Risa Tsuruta , Yasuhiro Tsutsui , Noritomo Fujino , Ayumu Mori
IPC分类号： C07D417/12 , C07D417/04 , C07D277/20 , C07D277/28 , C07D277/30 , C07D277/34 , C07D277/48 , C07D277/56 , C07D285/08
CPC分类号： C07D417/12 , C07D277/20 , C07D277/28 , C07D277/30 , C07D277/34 , C07D277/48 , C07D277/56 , C07D285/08 , C07D417/04
摘要： An amidine compound represented by formula (I) (wherein A1 represents a nitrogen atom or a group represented by formula CR6; A2 and A3 are the same as or different from each other and independently represent a nitrogen atom or a group represented by formula CH; R1 represents an aryl group which may be substituted by 1 to 5 substituents independently selected from a substituent group (2) or the like; R2 and R3 are the same as or different from each other and independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 haloalkyl group or a C1-6 alkoxy group; and R4 and R5 are the same as or different from each other and independently represent a hydrogen atom, a C1-6 haloalkyl group, a C1-6 alkyl group or the like) or a salt thereof. The compound is useful as an anti-fungal agent.
摘要翻译：由式（I）表示的脒化合物（其中A1表示氮原子或式CR6表示的基团; A2和A3彼此相同或不同，并且独立地表示氮原子或由式CH表示的基团; R1表示可以被1〜5个独立地选自取代基（2）等的取代基取代的芳基; R2和R3彼此相同或不同，独立地表示氢原子，卤素原子， C 1-6烷基，C 1-6卤代烷基或C 1-6烷氧基; R 4和R 5彼此相同或不同，独立地表示氢原子，C1-6卤代烷基，C1 -6烷基等）或其盐。该化合物可用作抗真菌剂。

33. 发明申请

US20110288293A1 ISOQUINOLINE DERIVATIVE 失效
标题翻译：异喹啉衍生物
公开(公告)号：US20110288293A1
公开(公告)日：2011-11-24
申请号：US13142230
申请日：2009-12-25
申请人： Tetsuo Takayama , Hajime Asanuma , Daisuke Wakasugi , Rie Nishikawa , Yoshinori Sekiguchi , Madoka Kawamura , Naoya Ono , Tetsuya Yabuuchi , Takahiro Oi , Yusuke Oka , Shoichi Kuroda , Fumito Uneuchi , Takeshi Koami
发明人： Tetsuo Takayama , Hajime Asanuma , Daisuke Wakasugi , Rie Nishikawa , Yoshinori Sekiguchi , Madoka Kawamura , Naoya Ono , Tetsuya Yabuuchi , Takahiro Oi , Yusuke Oka , Shoichi Kuroda , Fumito Uneuchi , Takeshi Koami
IPC分类号： C07D413/12 , C07D401/12 , C07D405/12 , C07D217/24 , C07D409/12 , C07D471/04 , C07D401/06 , C07D217/16 , C07D417/12
CPC分类号： C07D217/16 , C07D217/18 , C07D217/20 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐具有抑制CRTH2的作用，因此可用作哮喘，特应性皮炎和过敏性鼻炎等过敏性疾病的预防或治疗。

34. 发明授权

US08048898B2 Inhibitor of binding of S1P1 失效
标题翻译：抑制S1P1的结合
公开(公告)号：US08048898B2
公开(公告)日：2011-11-01
申请号：US12671401
申请日：2008-08-01
申请人： Naoya Ono , Fumiyasu Shiozawa , Tetsuya Yabuuchi , Hironori Katakai
发明人： Naoya Ono , Fumiyasu Shiozawa , Tetsuya Yabuuchi , Hironori Katakai
IPC分类号： C07D413/14 , C07D413/12 , C07D401/14 , C07D401/12 , C07D213/70 , C07D213/68 , C07D213/643 , A61K31/5377 , A61K31/496 , A61K31/4725 , A61K31/4709 , A61K31/4439 , A61K31/4436 , A61K31/443 , A61K31/44
CPC分类号： C07D213/64 , C07D213/68 , C07D213/70 , C07D213/71 , C07D239/34 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y1 is CRA, Y2 is CRB and Y3 is CRC), X represents an oxygen atom, etc., R1 represents a C1-C6 alkyl group, etc., R2 represents a C1-C6 alkyl group, etc., R3 represents an optionally substituted phenyl group, etc., R4 represents a hydrogen atom, etc., and R5 represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐：（其中Y1表示氮原子或由CRA表示的基团，Y2表示氮原子或由CRB表示的基团，Y3表示氮原子或表示通过CRC，RA，RB和RC可以相同或不同，各自表示氢原子等（不包括Y1为CRA，Y2为CRB且Y3为CRC的情况），X为氧原子等 R1表示C1-C6烷基等，R2表示C1-C6烷基等，R3表示可以具有取代基的苯基等，R4表示氢原子等，R5表示任选取代的苯基等）对S1P与其受体Edg-1（S1P1）之间的结合具有抑制作用，并且可用作自身免疫性疾病，类风湿性关节炎，哮喘，特应性皮炎，器官移植后的排斥反应的治疗剂，癌症，视网膜病变，牛皮癣，骨关节炎或年龄相关黄斑变性等

35. 发明申请

US20100234594A1 INHIBITOR OF BINDING OF S1P1 失效
标题翻译： S1P1结合抑制剂
公开(公告)号：US20100234594A1
公开(公告)日：2010-09-16
申请号：US12671401
申请日：2008-08-01
申请人： Naoya Ono , Fumiyasu Shiozawa , Tetsuya Yabuuchi , Hironori Katakai
发明人： Naoya Ono , Fumiyasu Shiozawa , Tetsuya Yabuuchi , Hironori Katakai
IPC分类号： C07D413/12 , C07D239/34 , C07D401/12
CPC分类号： C07D213/64 , C07D213/68 , C07D213/70 , C07D213/71 , C07D239/34 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: (wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y1 is CRA, Y2 is CRB and Y3 is CRC), X represents an oxygen atom, etc., R1 represents a C1-C6 alkyl group, etc., R2 represents a C1-C6 alkyl group, etc., R3 represents an optionally substituted phenyl group, etc., R4 represents a hydrogen atom, etc., and R5 represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P1), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.
摘要翻译：由式（I）表示的化合物或其药学上可接受的盐：（其中Y1表示氮原子或由CRA表示的基团，Y2表示氮原子或由CRB表示的基团，Y3表示氮原子或表示通过CRC，RA，RB和RC可以相同或不同，各自表示氢原子等（不包括Y1为CRA，Y2为CRB且Y3为CRC的情况），X为氧原子等 R1表示C1-C6烷基等，R2表示C1-C6烷基等，R3表示可以具有取代基的苯基等，R4表示氢原子等，R5表示任选取代的苯基等）对S1P与其受体Edg-1（S1P1）之间的结合具有抑制作用，并且可用作自身免疫性疾病，类风湿性关节炎，哮喘，特应性皮炎，器官移植后的排斥反应的治疗剂，癌症，视网膜病变，牛皮癣，骨关节炎或年龄相关黄斑变性等

36. 发明授权

US4680270A Method and apparatus for conducting flow analysis 失效
标题翻译：进行流量分析的方法和装置
公开(公告)号：US4680270A
公开(公告)日：1987-07-14
申请号：US509050
申请日：1983-06-29
申请人： Hiroshi Mitsumaki , Nobuyoshi Takano , Naoya Ono
发明人： Hiroshi Mitsumaki , Nobuyoshi Takano , Naoya Ono
IPC分类号： G01N33/487 , G01N33/49 , G01N35/00 , G01N35/08 , G01N27/40
CPC分类号： G01N33/4915 , G01N35/00 , G01N35/08 , Y10T436/117497
摘要： A single sampling tube is inserted into a whole blood sample contained in a sample cup, and the blood introduced into a switch-valve and a first channel without being diluted. The switch-valve has a volumetric section. In the first channel are arranged a plurality of ion-sensing electrodes, and downstream from these electrodes, a sample position sensor. The blood is led up to where the sample position sensor is located, at which point it fills the volumetric section and the ion sensing electrode channels. The sample Na.sup.+, K.sup.+, Cl.sup.-, and Ca.sup.++ are detected in this state. After the switch-valve switches, the flow within the volumetric section is forced towards a photometer positioned in a second channel by a reagent solution. The blood is diluted while passing through a reaction coil, during which time enzymes in the blood give rise to enzyme reactions with the reagents. The absorbance of the reaction solution is measured by the photometer.
摘要翻译：将单个采样管插入到包含在样品杯中的全血样品中，并且将血液引入开关阀和第一通道而不被稀释。开关阀具有容积部分。在第一通道中布置有多个离子感测电极，并且在这些电极的下游布置有样品位置传感器。血液被引导到样品位置传感器所在的位置，此时它将填充体积部分和离子感测电极通道。在该状态下检测到样品Na +，K +，Cl-和Ca ++。在开关阀切换之后，容积部分内的流量被试剂溶液强制位于第二通道中的光度计。血液在通过反应线圈时被稀释，在此期间，血液中的酶会与试剂引起酶反应。通过光度计测量反应溶液的吸光度。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式